Non-Hodgkin Lymphoma Diagnostics Market to Observe Utmost CAGR of 8.5% by 2030

Published June 19, 2023

Non-Hodgkin Lymphoma Diagnostics MarketGlobal Non-Hodgkin Lymphoma Diagnostics Market research report presents data and information about the scenario of HEALTHCARE industry which makes it easy to be ahead of the competition in today’s speedily changing business environment. An array of objectives of the marketing research has been considered to generate this best market report. This market document is great source to not only achieve insights into revenue growth and sustainability initiative but also to know the businesses with most-detailed market segmentation in the industry. The comprehensive Global Non-Hodgkin Lymphoma Diagnostics Market report is all-encompassing and object-oriented that has been planned with the grouping of an admirable industry experience, inventive solutions, industry insight and most modern tools and technologies.

The increasing awareness about non-Hodgkin lymphoma globally has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market’s growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved diagnostic processes and techniques also contributes to the rising demand for non-Hodgkin lymphoma diagnostics testing.

The global non-Hodgkin lymphoma diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the global non-Hodgkin lymphoma diagnostics market will grow at a CAGR of 8.5% during the forecast period of 2023 to 2030.

Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @

The global non-Hodgkin lymphoma diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The increasing research in the field of non-Hodgkin lymphoma diagnosis and development is further boosting the market growth. However, difficulties in non-Hodgkin lymphoma screening techniques might hamper the growth of the global non-Hodgkin lymphoma diagnostics market in the forecast period.

Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.

Cancer begins in the lymphs and most often occurs in people who smoke. Two major types of non-Hodgkin lymphoma are aggressive non-Hodgkin lymphoma and indolent non-Hodgkin lymphoma. Causes of non-Hodgkin lymphoma include smoking, second-hand smoke, exposure to certain toxins, and family history.

Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don’t appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.

This Market Intelligence Report Analyses Some of the Most Crucial Concerns:

  • How will the major segments of this international market develop over the next few years?
  • Who are the major players that will dominate the market in the future?
  • When it comes to this industry, who are the top suppliers and producers?
  • How have the most successful companies in the industry planned for future growth and expansion?
  • In what sectors might we expect to see the greatest increase in demand over the coming years?
  • How many distinct subsets of buyers make up this market?
  • Which regional powerhouse do you foresee as becoming the largest player in the international market?
  • Does a new coronavirus pandemic have any consequences?
  • In what ways are established actors stymied by the entry of newcomers, and how may they be overcome?

Recent Development

  • In November 2022, Danaher. announced that it had entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. The program invests in product innovation to advance external R&D strategies with a focus on genomic medicines, precision diagnostics, next generation biomanufacturing, human systems, and data sciences.
  • In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and global presence in the market.

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@

Global Non-Hodgkin Lymphoma Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

  • Increased Growth in Prevalence of Non-Hodgkin Lymphoma

Lymphoma is the general name for many related subtypes of cancer that arise from a type of white blood cell called a “lymphocyte.” Lymphoma is divided into two major categories Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). Non-Hodgkin’s lymphoma is a general category of lymphoma. There are many subtypes that fall into this category. Diffuse large B cell lymphoma and follicular lymphoma are among the most common subtypes. Lymphoma cancer cases are rising worldwide. Non-Hodgkin Lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers.

The chance that a man will develop NHL in his lifetime is about 1 in 43; for a woman, the risk is about 1 in 53. In 2020, as per the International Agency for Research on Cancer by World Health Organization (WHO), there were an estimated 544,352 people found to be diagnosed with non-Hodgkin lymphoma worldwide.

  • Increase in Awareness Regarding Non-Hodgkin Lymphoma

The non-Hodgkin lymphoma awareness is a chance to increase knowledge about these diseases and to spotlight research into their causes, prevention, diagnosis, treatment, and survival. The objective is to assist persons who have been impacted by lymphoma and to promote healthy habits.

The fifth most prevalent cancer in the world is lymphoma. As per the report by World Health Organization, Asia has the highest incidence rate of 241,270 patients for the past 5 years. Also, non-Hodgkin lymphoma accounts for 7.4% of all cancer deaths in Asia. The death rate has very slowly increased each year.

Every year, several awareness campaigns, webinars, and conferences are planned around the globe to educate people about non-Hodgkin lymphoma, and various organizations take the lead in these campaigns. As a result, this is expected to drive the growth of the global non-Hodgkin lymphoma diagnostics market.

  • Lack of Availability of Trained and Skilled Medical Professionals

The density of the total health workforce is estimated to be 29 per 10,000 population but only 16 per 10,000 for trained workers. The requirement for skilled and certified professionals is a big restraint for the global non-Hodgkin lymphoma diagnostics market. The demand for fluorescent in situ hybridization is increased due to increasing cases of cancer diseases and genetic anomalies, but the less number of skilled professionals present is expected to hamper the growth of the market.

The ability of a qualified medical practitioner to conduct numerous tests is crucial to the growth of the healthcare and medical sectors. The main goal of having a professional team is to guarantee that every piece of life-saving medical equipment will function effectively when it is most needed. The technician needs to have the appropriate education and certification from the relevant manufacturers and authorities.

Technicians face technical training gaps related to problems adapting advanced methods safely to perform procedures efficiently. For the diagnosis of lymphoma, there is a high need for skilled professionals for method development, validation, operation, and troubleshooting activities

  • Stringent Regulations and Guidelines for Different Treatments and Diagnosis

Selling medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or considered, delays can seriously jeopardize the likelihood of success in a highly competitive market. But their approval and marketing in multiple regions across the globe require meeting stringent regulatory standards and acceptance by various regulatory bodies.

Global Non-Hodgkin Lymphoma Diagnostics Market Segmentation


  • Imaging
  •  Biopsy
  •  Immunohistochemistry
  •  Biomarker Test
  •  Genetic Test
  •  Cytogenetics
  •  Lumbar Puncture (Spinal Tap)
  •  Blood Test
  •  Cytochemistry
  •  Others


  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV


  • Aggressive Lymphomas
  • Indolent Lymphomas


  • Instrument Based Products
  • Platform Based Products
  • Kits And Reagents
  • Other Consumables


  • Fluorescent In Situ Hybridization
  • Next Generation Sequencing
  • Fluorimmunoassay
  • Comparative Genomic Hybridization
  • Immunohistochemical
  • Others


  • Screening
  • Diagnostic And Predictive
  • Prognostic
  • Research


  • Hospitals
  • Diagnostic Centers
  • Cancer Research Centers
  • Academic Institutes
  • Ambulatory Surgical Centers
  • Others


  • Direct Tender
  • Retail Sales
  • Others


Browse the complete table of contents at –

Top DBMR Healthcare Reports:       

Non-Hodgkin Lymphoma Diagnostics Market – Industry Trends and Forecast to 2030

Europe Non-Hodgkin Lymphoma Diagnostics Market – Industry Trends and Forecast to 2030

Asia-Pacific Non-Hodgkin Lymphoma Diagnostics Market – Industry Trends and Forecast to 2030

Middle East and Africa Non-Hodgkin Lymphoma Diagnostics Market – Industry Trends and Forecast to 2030

North America Non-Hodgkin Lymphoma Diagnostics Market – Industry Trends and Forecast to 2030

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475


CDN Newswire